Innate Pharma (IPHA) Total Current Liabilities (2017 - 2025)
Innate Pharma's (IPHA) quarterly Total Current Liabilities came in at $42.7 million in Q4 2025, up 21.04% YoY from $35.2 million in Q4 2024, and up 28.08% on a QoQ basis from $33.3 million in Q2 2025.
Innate Pharma (IPHA) Total Current Liabilities (2017 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 9 years of Total Current Liabilities data on file, last reported at $42.7 million in Q4 2025.
- Quarterly Total Current Liabilities rose 21.04% year-over-year to $42.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $42.7 million (up 21.04% YoY) and the FY2025 annual result came in at $42.7 million, up 21.04% from the prior year.
- Total Current Liabilities advanced to $42.7 million in Q4 2025, from $33.3 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $91.4 million in Q4 2021 to a low of $33.3 million in Q2 2025.
- A 5-year average of $49.9 million and a median of $42.4 million in 2022 frame the typical range for Total Current Liabilities.
- The widest YoY moves for Total Current Liabilities: up 68.5% in 2021, down 99.94% in 2021.
- Tracing IPHA's Total Current Liabilities over 5 years: stood at $91.4 million in 2021, then slumped by 53.85% to $42.2 million in 2022, then climbed by 1.12% to $42.6 million in 2023, then decreased by 17.36% to $35.2 million in 2024, then increased by 21.04% to $42.7 million in 2025.
- The last three Total Current Liabilities figures came in at $42.7 million (Q4 2025), $33.3 million (Q2 2025), and $35.2 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Innate Pharma | 202.03 Mn | 202.03 Mn | - | 42.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 42.66 Mn |
| Jun 30, 2025 | 33.31 Mn |
| Dec 31, 2024 | 35.24 Mn |
| Jun 30, 2024 | 41.16 Mn |
| Dec 31, 2023 | 42.65 Mn |
| Jun 30, 2023 | 41.02 Mn |
| Dec 31, 2022 | 42.17 Mn |
| Jun 30, 2022 | 78.49 Mn |
| Dec 31, 2021 | 91.39 Mn |
| Jun 30, 2021 | 51.32 Mn |
| Dec 31, 2020 | 54.23 Mn |
| Jun 30, 2020 | 82.35 Bn |
| Dec 31, 2019 | 134.84 Mn |
| Dec 31, 2018 | 224.92 Mn |
| Dec 31, 2017 | 87.02 Mn |